Phone

0510-88276733

Store

TikTok Shop

JD Shop

Tmall

R&D and Innovation

R&D Strengths

Product Development Of Many Different Formulations

Creams

View Details

Ointments

View Details

Gels

View Details

Solutions

View Details

Sprays

View Details

Liniments

View Details

Film-Forming Topical Preparations

View Details

Lotions

View Details

Advanced Manufacturing
Technology Platform

Topical medicine products are very complex. Their development faces multiple challenges, including complex structures, complex compositions, and specific delivery requirements.

Active ingredients must penetrate the stratum corneum and reach target tissues while minimizing irritation. Products must also maintain good stability and a pleasant user experience to support patient adherence.

From small-scale research to commercial production, topical formulations also face scale-up challenges. Multiphase systems are highly sensitive to process parameters such as shear force and temperature control, making large-scale manufacturing technically demanding.

To address these challenges, Ziyond Pharmaceutical has built a systematic and closed-loop R&D ecosystem:
Topical Drug Development and Evaluation Technology Platform
TDDET

Compound antioxidant technology
Poly-emulsification technology
Packaging system research technology
Microstructure research technology

In Vitro Release and Skin Penetration Research Platform
D3-PK

Mass spectrometry imaging, MSI, and high-sensitivity LC-MS/MS technology
Fully automated transdermal diffusion system
Tape stripping technology

Topical Formulation Scale-Up Platform
TPSP

Process scale-up parameter optimization based on data accumulation
Real-time online monitoring of key process indicators
Embedded GMP-compliant scale-up management throughout the full process

25-Indicator Q3 Quality System

Appearance and texture characterization,
Emulsion type characterization,pH value,
Phase characterization,Particle size,
Oil phase characterization,Crystal form,
Rheological properties,Crystal habit,
Oil phase characterization,Crystal form,
Specific gravity,Droplet size,Drying rate,
Moisture content,Water activity,
Deformation-related properties
......

R&D Platforms

JITRI–Ziyond Pharmaceutical
Joint Innovation Center

June 2021

JSIFDC–Ziyond Pharmaceutical
Joint Laboratory for In Vitro Evaluation of Topical Formulations

September 2024

China Pharmaceutical University–Ziyond Pharmaceutical
Joint Laboratory for Dermatological Pharmaceutical Excipients

February 2024

Jiangnan University–Ziyond Pharmaceutical
Joint Research Laboratory

April 2021

Lubrizol–Ziyond Pharmaceutical
Joint Technology Development Platform

September 2022

Thermo Fisher Scientific–Ziyond Pharmaceutical Joint Laboratory

July 2024

SCIEX China–Ziyond Pharmaceutical
Joint Laboratory for Transdermal Testing of Topical Formulations

November 2024

LOGAN–Ziyond Pharmaceutical
Joint Laboratory

August 2021

China–Korea–Austria Doctoral
Joint ZR Global Dermatology Laboratory

September 2025

Jiangnan University–Ziyan Bio
Joint Research Laboratory

March 2022

Shanghai University–Ziyan Bio
Joint Laboratory and Strategic Partnership

November 2025

The First Hospital of China Medical University
Ziyan Bio
Joint Research Center for Skin Care

November 2023

Wuxi Institute for Food and Drug Control–Ziyan Bio
Strategic Partnership and Joint Research Center

January 2024

LOGAN–Ziyan Bio
Joint Laboratory for Cosmetic Transdermal Absorption Research

May 2024
R&D Updates

ZIYOND has built a comprehensive treatment layout in China’s dermatology market, covering skin health needs from head to toe.

Approved in-house products
Drug registration approvals
Valid cosmetic product filings
Products under development
Authorized patents
Authorized invention patents
Products under dual China–U.S. registration: 3

ZIYOND has established a comprehensive R&D system for topical dermatological formulations, supporting differentiated product development and sustainable competitive advantages.

The company’s R&D base is located in Xishan District, Wuxi, with more than 3,000 square meters of R&D and pilot-scale facilities. It includes R&D laboratories and pilot research platforms, equipped with professional facilities for formulation development, analytical method development, and stability studies.

The laboratory has obtained CNAS accreditation and completed BSL-2 laboratory registration.

How We Make R&D Innovation Perceivable to Consumers

Skin is the largest organ of the human body, and skin diseases are among the most common disease categories worldwide.

ZIYOND remains focused on dermatology and integrates R&D, manufacturing, and sales. The company has built a product ecosystem characterized by broad product variety, complete dosage forms, proven efficacy, and wide category coverage.

This ecosystem is designed to meet multi-level consumer needs, from clinical treatment to daily functional skin care.

● Full Coverage from Head to Toe: The company’s products address skin health needs across the scalp and hair, face, trunk, limbs, and nails.

● Coverage of Common Skin Problems: The company’s products cover common skin problems, including fungal infections, acne and rosacea, eczema, dermatitis, psoriasis, and pigmentary skin diseases.

● R&D Product Layout: As of December 31, 2025, the company focused on six major dermatological disease areas, with more than 110 marketed products and over 30 products under development.

To further strengthen its leadership in China’s dermatology market, ZIYOND plans to launch 15 to 20 new products over the next three to five years.

● Product Efficacy and User Feedback: ZIYOND’s R&D innovation is driven by patient clinical needs. In addition to clinical research, the company has used feedback data from more than 1.7 million real-world users to continuously improve product efficacy, safety, and adherence.

The company integrates consumer-perceivable innovation throughout the R&D process.

Why Dosage Form Diversity Matters

In dermatological treatment, drug efficacy depends not only on the active ingredient, but also on the patient’s willingness to use the product.

Heavy or irritating textures may lead patients to discontinue treatment early. Therefore, ZIYOND focuses on solving specific usage barriers during formulation design, rather than only meeting basic compliance requirements.

Based on its proprietary platforms, the company can select suitable dosage forms for different application sites. It has established production lines for eight topical dosage forms, including creams, ointments, gels, solutions, lotions, sprays, liniments, and film-forming topical preparations.

This enables the company to better match patient needs and improve efficacy, adherence, and convenience.

In addition, the company’s integrated R&D and manufacturing system supports efficient technology transfer and quality control, ensuring smooth transition from R&D to commercial production. It also allows flexible adjustment of production volume and product mix according to market demand.